Radgocitabine is under clinical development by Delta-Fly Pharma and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Radgocitabine’s likelihood of approval (LoA) and phase transition for Refractory Acute Myeloid Leukemia took place on 05 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 05 Dec 2022 increased Radgocitabine’s LoA and PTSR for Relapsed Acute Myeloid Leukemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Radgocitabine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Radgocitabine overview

Radgocitabine (DFP-10917) is under development for the treatment of relapsed and refractory acute leukemias including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). The drug candidate is administered as an intravenous infusion. It is a deoxycytidine analog that targets G2/M phase of the cell cycle.

Delta-Fly Pharma overview

Delta-Fly Pharma is a biopharmaceutical and healthcare company. The company discovers and develops anti-cancer agents. It’s product portfolio includes DFP-10917, for the treatment of myelogenous leukemia; DFP-14323, an anticancer drug candidate treating lung cancer; DFP-10825, liposome-conjugated RNAi molecule which targets disseminated ovarian and gastric cancer. Delta-Fly Pharma also develops DFP-11207, cancer cell metabolism regulator that treats stomach cancer; DFP-14927, Polymeric anti-cancer agent for the treatment of solid tumors. The company develops novel products using module technology (Module Drug Discovery). It has its operations in Japan, Canada, and China. Delta-Fly Pharma is headquartered in Tokushima-Shi, Tokushima, Japan.

Quick View Radgocitabine LOA Data

Report Segments
  • Innovator
Drug Name
  • Radgocitabine
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.